Pliant Therapeutics Inc
9PT
Company Profile
Business description
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Contact
331 Oyster Point Boulevard
South San FranciscoCA94080
USAT: +1 650 481-6770
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
171
Stocks News & Analysis
stocks
Undervalued by 17%, this US cybersecurity leader is a buy for 2026
Here’s a wide-moat company with strong secular tailwinds in a promising industry—and an attractive stock price, too.
stocks
Tough conditions for ASX listed wagering leader
Wagering continues to be challenged in Australia.
stocks
Chart of the Week: Inflation fears dampen sentiment on retailers
Rising inflation is the fly in the ointment.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,045.90 | 27.80 | -0.31% |
| CAC 40 | 8,348.82 | 105.36 | 1.28% |
| DAX 40 | 25,230.16 | 102.70 | 0.41% |
| Dow JONES (US) | 49,256.68 | 9.43 | -0.02% |
| FTSE 100 | 10,121.61 | 76.92 | 0.77% |
| HKSE | 26,231.79 | 82.48 | 0.32% |
| NASDAQ | 23,512.84 | 32.82 | 0.14% |
| Nikkei 225 | 51,939.89 | 822.63 | 1.61% |
| NZX 50 Index | 13,696.25 | 20.61 | -0.15% |
| S&P 500 | 6,936.50 | 15.04 | 0.22% |
| S&P/ASX 200 | 8,717.80 | 29.10 | -0.33% |
| SSE Composite Index | 4,120.43 | 37.45 | 0.92% |